A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
An international registry was used to identify 5783 women with a BRCA1 or BRCA2 mutation, who then completed a baseline questionnaire and at least one follow-up questionnaire. The participants were observed until they were diagnosed with ovarian, fallopian, or peritoneal cancer, death, or date of most recent follow-up. The goal was to assess the impact of prophylactic oophorectomy on all-cause mortality and estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort.
After average follow up of 5.6 years, a total 186 women developed ovarian (n=132), fallopian (n=22), or peritoneal (32) cancer, 68 of whom have died. Bilateral oophorectomy was associated with a hazard ratio (HR) for ovarian, fallopian, or peritoneal cancer of 0.20 (95% CI, 0.13 to 0.30; P< .001). The HR for all-cause mortality at age 70 years associated with oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P< .001) for women who had no history of cancer at baseline.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Study reveals critical gaps in care for PCOS patients
May 17th 2024A new study presented at the 2024 ACOG Annual Clinical and Scientific Meeting highlighted significant gaps in polycystic ovary syndrome (PCOS) care, revealing widespread patient dissatisfaction and the urgent need for improved provider education and comprehensive treatment approaches.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More